FDA Grants JCAR017 Breakthrough Designation for Non-Hodgkin Lymphoma

21 dicembre 2016 – JCAR017 has received an FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory, aggressive large B-cell non-Hodgkin lymphoma (NHL), according to Juno and Celgene, the codevelopers of the CD19-targeted CAR T-cell therapy. The designation is specifically for patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma, or not otherwise specified … (leggi tutto)